title: [Renal aspects of sodium glucose cotransporter 2 inhibitors].
abstract: It has been known for centuries that the kidneys play a role in glucose homeostasis, yet the underlying tubular mechanisms have only been recently identified by studying patients with familial glucosuria. These insights have lead to the commercialization of a novel class of oral antidiabetic agents named gliflozines. Gliflozines induce renal glucosuria by blocking the Na-glucose cotransporter SGLT2, localized in the proximal tubule, and allow a reduction of 0.5 to 1% of glycated hemoglobin. They also diminish proximal sodium reabsorption, and reduce the glomerular hyperfiltration that is often seen in the early stages of diabetes. Preliminary data suggest that they may decrease blood pressure and have renoprotective effects. This article provides an overview of the role of kidneys in glucose homeostasis and the renal effects of SGLT2-inhibitors.
authors.forename: F
authors.initials: F
authors.lastname: Beaud
authors.forename: M
authors.initials: M
authors.lastname: Pruijm
authors.forename: A
authors.initials: A
authors.lastname: Humbert
authors.forename: M
authors.initials: M
authors.lastname: Burnier
authors.forename: A
authors.initials: A
authors.lastname: Zanchi
mesh_terms: D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000502:physiology; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D000077203:Sodium-Glucose Transporter 2 Inhibitors